Executive Summary

Vision and Opportunity 

Simplr International, an established provider of regenerative medicine in Australia, seeks to expand its innovative healthcare offerings to Indonesia by establishing a Regenerative Medicine and Longevity Clinic in BSD City’s Special Economic Zone (SEZ). This clinic will introduce cutting-edge treatments, focusing on regenerative medicine, cognitive therapies, metabolic health, and aesthetic wellness, with a commitment to preventative and personalized care. Leveraging BSD City's advanced infrastructure and Simplr's global partnerships, the clinic aims to address Indonesia's rising prevalence of non-communicable diseases (NCDs) and capitalize on the region's growing demand for high-quality medical services.

Market Landscape 

Indonesia presents a lucrative market for regenerative healthcare, driven by increasing life expectancy, disposable income, and the increasing prevalence of chronic conditions such as diabetes, obesity, and neurodegenerative diseases. With approximately 2 million Indonesians traveling abroad for advanced medical care annually, the clinic offers a competitive local alternative. Targeting affluent Indonesians and international health tourists, Simplr Health aligns with global trends, as the regenerative medicine market is projected to grow at a compound annual growth rate (CAGR) of 16.79%, with significant growth in the Asia-Pacific region.

Services and Patient Focus 

Simplr’s Regenerative Medicine and Longevity Clinic will provide:

• Stem Cell and Cellular Therapies: Such as Mesenchymal Stem Cells (MSC) and Platelet-Rich Plasma (PRP) and effective for chronic pain, osteoarthritis, neurodegenerative diseases, and diabetes.

• Cognitive Enhancement: Therapies such as hyperbaric oxygen therapy and neurofeedback improve brain function and promote independence in aging populations.

• Aesthetic Rejuvenation: Anti-aging treatments enhancing skin elasticity and youthfulness through advanced technologies like Morpheus9 and platelet-rich plasma (PRP).

Key patient groups include those suffering from diabetes, cardiovascular issues, neurodegenerative disorders, post-stroke, musculoskeletal conditions, and individuals seeking preventive or aesthetic health solutions. Treatments are designed with a personalized, holistic approach, addressing underlying causes and delivering long-term health benefits. In a later phase Immune Cell Therapy (ICT) for cancer patients will be added. This cutting-edge treatment developed and offered by one of Simplr’s partners in Japan shows improving survival rates by 30-50% for solid tumors.

Competitive Advantages 

Simplr Health distinguishes itself from existing clinical providers of MSC and PRP and aesthetic rejuvenation treatments in Indonesia through: 

1. World-Class Expertise: Collaboration with renowned global specialists ensures access to the latest innovations in regenerative medicine. 

2. Regulatory Compliance: Approved therapies from countries leading in medical standards (e.g., Japan, the US) ensure safety and efficacy. 

3. Comprehensive Offerings: Integrated, personalized protocols for chronic and degenerative conditions, aesthetic rejuvenation, and cognitive enhancements. 

4. Strategic Partnerships: Collaborations with SingMedic and local SEZ authorities streamline operations and patient access. 

5. Optimal Location: Situated in BSD City, the clinic benefits from proximity to Jakarta, regulatory incentives, and access to a growing affluent population.

Financial Outlook 

With an initial investment of USD 999,688 to fit out and commission a clinic of 294m2 in the Science Tower in BSD, the clinic expects to achieve breakeven by the fifth month of operation, leveraging a revenue model built on personalized treatment protocols averaging $12,000 per patient. Over five years, Simplr projects a robust net present value (NPV) of $31.51 million and an internal rate of return (IRR) of 138.6%. Key financial drivers include high patient retention, scalable service offerings, and a gradual ramp-up to 80 patients per month by year four.

Implementation Plan 

The clinic’s phased approach begins with core regenerative therapies, expanding to advanced offerings like immune cell therapy for cancer and stem cell banking and cryopreservation. Simplr will employ a lean organizational structure initially with only 12 staff members and a rotating team of international specialists. They will be supported by an experienced Scientific Advisory Board.

Simplr Health Indonesia's marketing and sales strategy focuses on establishing the clinic as a leader in regenerative medicine by leveraging its global partnerships, evidence-based treatments, and strategic location in BSD City. Key initiatives include educating physicians, running targeted digital campaigns, forming partnerships with medical concierge services and luxury brands, and showcasing patient success stories. Simplr aims to attract affluent local patients and retain outbound medical tourists through regulatory-approved therapies and exceptional outcomes. Sales efforts will utilize SingMedic's network, BSD's promotional channels, and active social media engagement to reach its target audience.

Conclusion 

Simplr Health Indonesia’s Regenerative Medicine Clinic represents a transformative opportunity to redefine healthcare in the region. Combining global expertise, innovative treatments, and strategic positioning within a thriving SEZ, Simplr aims to improve lives, reduce healthcare burdens, and drive economic productivity while establishing itself as the premier regenerative medicine provider in Indonesia.

1. Company Description

1.1 Introduction

Simplr Health International (Simplr), in partnership with a global network of clinical and scientific experts, proposes Indonesia’s first Regenerative Medicine & Longevity Clinic within BSD City’s Special Economic Zone (SEZ). This clinic will introduce precision healthcare solutions, specializing in regenerative medicine, cognitive therapies, metabolic health, and aesthetic wellness. Positioned within the SEZ, the clinic will leverage international expertise and the latest therapeutic technologies from countries including Japan, Australia, and the United States.

BSD City, formerly referred to Bumi Serpong Damai (BSD) is a planned community located within Greater Jakarta in Indonesia. The project was initiated in 1984 by a group of private developers and started in 1989. The town is currently managed by the holding company PT Bumi Serpong Damai Tbk, which is owned by Sinar Mas Land, a subsidiary of the Sinar Mas Group.. BSD City encompasses a total area of approximately 6,000 hectares, hosting a range of residential houses, apartments, malls, offices, and more. Most of the residential areas are designed to be suitable for Indonesia's upper-middle class,in gated neighbourhoods, each with different themes. The city is now a self-sustaining community, with businesses, schools, shopping malls, hospitals and hotels. In one of the latest developments – in the Science tower of the Digital Hub – there is an option to start a state-of-the art clinic.

1.2 Company Structure and Ownership

Simplr International Pty Ltd will establish an SPV in the form of a PT PMA (‘Simplr Health Indonesia’) domiciled in BSD for the purpose of providing regenerative healthcare services in BSD.

The initial proposed structure is for Sinarmas to hold 30% and Simplr International and partners to hold 70% of Simplr Health Indonesia, with Dean Kilby proposed as Commissioner and a Sinarmas representative as a Director.

1.2 Mission Statement

Simplr Health Indonesia’s mission is to bring the promise of preventative and regenerative medicine to patients and practitioners.

We will achieve this with the most scientifically proven and innovative approaches to cell and tissue regeneration, disease reversal, and life extension – enabling better strategies for health and a bigger impact on quality of life.

1.3 Business History and Background 

Simplr Health has been delivering regenerative health services in Australia since 2011 through a partner network. Simplr International Pty Ltd was established in December 2022 to take Simplr Health’s capabilities into the international market.

In July 2023, Simplr International commissioned a feasibility study for a regenerative medicine offering in the Sanur special economic zone (SEZ). The study focussed on immune cell therapy to fit with the strategic priority of the Sanur SEZ. The study found the regional demand for regenerative healthcare to be large and growing, and the advantages of operating in a clear regulatory environment to be a distinct advantage in servicing both the Indonesian domestic and international health tourism markets. Simplr registered PT SMI in Indonesia in June 2023 as the SPV for the Sanur clinic and conducted a number of early-stage capital raises. Simplr is currently in due diligence with two potential investors for the final round of capital raising, subject to deadlines imposed by the SEZ manager, HIN.

Concurrent with the Sanur SEZ clinic, Simplr is in discussions with the largest health equipment manufacturing zone in the world, in Visakhapatnam, India, to provide regenerative healthcare services in the zone.

1.4 Location and Facilities 

Simplr Health Indonesia in BSD will be the second entity owned by Simplr International in Indonesia. The clinic will develop personalised regenerative therapeutic protocols for patients suffering from various diseases or disorders, or for those who wish for a more cosmetically focussed or preventive approach.

This core service can be expanded whilst the commercial viability has been demonstrated and forms the basis of the projected financial returns in the financial model. Once commercial viability is demonstrated, further services will be offered to augment the core offerings within the initial funding envelope and on the basis of supplier agreements, also within Phase 1.

Phase 2 would involve a second funding round to expand the core offering to include the likes of autologous and allogeneic immune cell therapies for cancer as well as cryopreservation facilities for cell banking, both of which require GMP certified laboratories. A separate financial model will be developed once Phase 1 has achieved breakeven, funded by a new funding round for equity in Simplr Health Indonesia.

2. Products and services

2.1 Patient groups

Simplr’s Regenerative Medicine & Longevity Clinic will introduce precision healthcare solutions, specializing in regenerative medicine, cognitive therapies, metabolic health, and aesthetic wellness. With this offering the clinic will tackle pressing non-communicable diseases (NCDs) increasingly prevalent in Indonesia, emphasizing personalized and preventive care.

Key patient groups include:

• Diabetes & Metabolic Disorders: With a rising prevalence of diabetes and metabolic syndrome, Simplr’s expertise in nutritional medicine offers targeted interventions that can reverse metabolic syndrome and support significant weight reduction, averaging 20-40% of total starting body mass. Furthermore, personalized therapies, such as stem cell and IV nutrient treatments, help improve insulin sensitivity and metabolic function and help treat or avoid complications.

• Obesity & Cardiovascular Health: Approximately 33% of Indonesian adults are overweight. Personalized interventions have shown a 58% reduction in diabetes onset, while immune-modulatory therapies help manage cardiovascular risks.

• Post-stroke treatments: Stroke is the number one cause of death and and major cause of disability in Indonesia. Compared to other countries in Southeast Asia, Indonesia has the highest age and sex-standardized mortality (193/100,000) and disability-adjusted life years lost (3,382/100,000) [2019]. The prevalence in urban areas and in higher income groups is higher. Utilizing the latest neuro-modulatory technologies such as transcranial magnetic stimulation, hyperbaric oxygen and photo biomodulation, together with advanced mapping of the brain’s connectome and function, has made possible a much more predictive approach to restoring and maintaining a healthy nervous system. The possibility of combining these strategies with the healing powers of regenerative medicine will make the SMI Facility unique and highly sought after.

• Joint pain and disfunction treatment: There are several causes of joint pain and disfunction. Osteoarthritis (OA) is the most common and has increasing prevalence due to aging, overweight and lifestyle changes. A 14.3% of the 272 million Indonesians suffers from OA. Whether acute injury or tissue degeneration over time, both can be successfully treated with stem cells and other regenerative techniques. Same day procedures as well as more long-term treatment plan options will allow patients to move better, live easier, and do more as a result of the extraordinary healing properties of MSCs on the musculoskeletal system. Significantly delaying or even outright avoidance of joint replacement surgery in a minimally invasive manner is fast becoming the preferred treatment option - and the SMI Facility will make this an accessible possibility for those in need.

• Cognitive Disorders: Dementia affects 1.2 million Indonesians. Therapies such as Hyperbaric Oxygen Therapy (HBOT) and neurofeedback/modulation have demonstrated cognitive improvements of 20-25%, promoting independence for aging adults.

• Cancer & Immunological Health: Cancer accounts for 18.8% of deaths in Indonesia, with immune cell therapies showing a 30-50% improvement in survival outcomes for cancers like melanoma.

The clinic aligns with Indonesia’s health goals by:

1. Reducing NCDs: Personalized treatments address diabetes, obesity, cardiovascular health, and neurodegeneration.

2. Promoting Healthy Aging: Cognitive longevity programs support independence and productivity in aging populations.

3. Improving Musculoskeletal Health: Non-surgical treatments reduce osteoarthritis-related disabilities.

4. Boosting Economic Productivity: Improved health outcomes decrease the healthcare burden, enhancing workforce productivity.

2.2 Regenerative programs and services

The conditions mentioned in 2.1 have almost always a multifactorial cause. It is therefore essential to focus on all different causes instead of only temporarily solving one aspect. Simplr’s Regenerative Medicine & Longevity Clinic offers for this purpose holistic and comprehensive treatment and prevention programs.

The clinic will provide three primary programs centered on personalized care:

1. Regenerative Wellbeing: Stem cell and immune cell therapies for chronic conditions and degenerative diseases.

2. Performance Wellbeing: Precision-driven treatments for physical and cognitive enhancement.

3. Aesthetic Wellbeing: Anti-aging therapies focused on internal rejuvenation.

All these programs consist of one or more evidence-based and personalized therapies:

1. Stem Cell and Cellular Therapies: Effective for chronic pain, osteoarthritis, and neurodegeneration, with studies showing a 70-80% improvement in pain reduction and joint function.

2. Immune Cell Therapy for Cancer: Led by Prof. Shigenori Goto, this therapy has shown a 30-50% survival rate improvement in cancers like melanoma.

3. Hyperbaric Oxygen Therapy (HBOT) and Neurofeedback: Spearheaded by experts such as Dr. Kristen Willeumier, Dr Eric Hansen and Prof Joseph Maroon, HBOT enhances neuroplasticity, showing cognitive gains of 20-25%.

4. Gut Microbiome Therapy and Fecal Microbiota Transplantation (FMT): With success rates of 85-90%, these therapies improve gut health and mental wellbeing.

5. Aesthetic Rejuvenation: Mesenchymal stem cells and PRP for anti-aging, enhancing skin elasticity and youthfulness and Morpheus treatment of the skin activating collagen production that induces remodeling.

6. Photobiomodulation and Plasma Exchange: Cellular repair for inflammation and degenerative conditions, promoting immune health and recovery.

All these treatment programs will be accompanies by dietary/metabolic and movement advise and coaching.

3.  Market Research and Analysis

3.1 Target Market

The target market for a clinic providing the holistic offerings of personalised therapies to the non-communicable disease conditions mentioned in chapter 2 is broad and growing. Due to increasing life-expectancy and changes in lifestyle due to increased disposable income, the number of patients with degenerative conditions such as diabetes, cardiovascular conditions, neurodegenerative diseases, and cancer, will increase dramatically in Indonesia over the next decades.

As the treatment will be out-of-pocket at the start, the primary target market will be affluent Indonesians that are currently using the first-tier private hospitals in Indonesia and/or travelling to e.g. Singapore and Malaysia at the moment for most of their health needs. A secondary target market of international patients exists, but is harder to reach and in their countries, there is in some cases already existing comparable offering.

3.2 Market size and trends

The global regenerative medicine market was valued at $30.43B USD in 2023 and is expected to grow at a CAGR of 16.79% from 2024 to 2030, with the second fastest growth expected in Asia Pacific. Factors contributing to this growth include advancements in technology, increasing incidence of chronic diseases, rising geriatric population, and growing awareness about regenerative medicine.

Based on prevalence and global numbers, the market size far exceeds the capacity of the proposed clinic in BSD. For three patient groups we have done a deeper study to numbers and a proxy assessment of the actual market size. For Osteoarthritis we also looked at affordability.

Diabetes

The prevalence of diabetes in Indonesia has increased from 6.2% in 2019 to 10.8% in 2021. It is expected to increase up to 16.1% in 2045 according to a study performed by the University of Indonesia (Global Burden of Disease). There will be more than 40 million Indonesians suffering from diabetes in 2045. Diabetes was by 2019 the 3rd cause of death in Indonesia (6.2%).

Stroke

Stroke, or cerebrovascular accidents are the number one cause of death in Indonesia. In 2019 a 19.5% of all death was due to a stroke. The incidence of stroke increased from 1990 to 2019 from 193 to 293 per 100,000 people. This means that almost 800,000 Indonesians every year get a stroke. Due to improved survival nowadays more than 50% survive a stroke. Most of them however with neurological deficits which lead to an increased number disability-adjusted life years lost (3,382/100,000).

According to the Indonesian Health Insurance (BPJS), in 2016, stroke health care costs were 1.43 trillion rupiah in 2016, it rose to 2.19 trillion Rupiah in 2017, and in 2018 it reached 2.57 trillion rupiah. Based on the Indonesian Family Life Survey (IFLS), the economic burden on households due to stroke was $0.29 billion in 2010.

Osteoarthritis

In 2020 in total 14.3% of all Indonesians suffered from osteoarthritis (prevalence). It is a chronic condition and not directly ‘cured’ by joint replacement. On average patients suffer around 15 years from OA. The incidence is estimated around 1%. This means that every year 2,720,000 new cases of OA are diagnosed in Indonesia.

In order to calculate the total number of OA patients that is eligible for advance regenerative treatment in our clinic, we assumed the percentage of OA patients that is currently getting a total joint replacement. According to the AGES-Reykjavik Study 1.4% of the OA patients per year get a joint replacement[1]. Extrapolated to Indonesia this means around 38,000 eligible patients per year.

In the feasibility study for the Sanur clinic, we assumed that people with a yearly household income more than USD 75,000 will be able to afford out-of-pocket treatment at our clinic. In Indonesia this is 3% of the households according to the World Inequity Database (WID).

The same analysis we did on Australian patient and population data. In the table below the estimated number of patients with OA that are eligible for joint replacement and can afford out-of-pocket treatment is projected for 2020 and until 2040 for both Indonesia and Australia.

Medical tourism

Another approach is looking at current numbers of Indonesians that travel to Singapore and Malaysia for medical treatment. Around 2 million Indonesians travel overseas every year to receive medical care[2]. Our partner SingMedic (HCM Medika) has been supporting Indonesians during their medical travel to amongst others Malaysia and Singapore. They have analysed 18,000 cases that went abroad for treatment between 2017 and 2023. A little more than 50% comes from Jakarta and West-Java. Orthopedic, gastroenterology and obgyn are the 3 most visited specialists in Malaysia and Singapore. Around 11% had orthopedic complaints. Extrapolated to the 2 million Indonesians traveling overseas every year, it will mean that around 110,000 people from Jakarta and West Java with orthopedic conditions travel every year abroad for advanced medical treatment.

3.3 Competitive Landscape

There are currently GMP certified laboratory facilities that process stem cells as well as clinical providers offering MSC and PRP treatments in Indonesia. The most direct competitor would likely be the Jakarta Stem Cell Centre where treatments including stem cells for aesthetics, mobility and joint enhancements, respiratory/skin/hair rejuvenation and metabolic booster infusions are tailored to individual patients. Other potential competitors include:

• Dr Yanti/Global Stem Cells Group (Bandung, Jakarta, Surabaya, Bali): stem cell treatments for rejuvenation, wound healing, diabetes, pain management, degenerative conditions.

• Asia Stem Cell Centre (Jakarta): stem cell processing lab and storage facility for cells and cell products for an extensive range of indications.

• Celltech Stem Cell Centre (Jakarta): stem cell expansion (autologous) and banking.

• Divine Plastic Surgery and Stem Cell Centre (Bali): PRP, stem cell treatments using autologous SVF, and hyperbaric oxygen therapy.

• ProSTEM (Jakarta): GMP cell processing and storage facility.

• Tristem Indonesia Cell Therapy Centre (Surakarta): Stem cell, PRP and Secretome manufacturing facility.

• Alster Lake Clinic (Sanur) is a European clinic that will open a clinic in the special economic zone in Sanur together with Jakarta Aesthetic Clinic and PT Asoka Bunga Khatulistiwa. They plan to offer cellular therapy for disease prevention, treatment and age reversing.

• Astana Genting Health & Wellness Centre (Sanur) will - In association with Cellularity, develop allogeneic cell therapies derived from the placenta and advanced biomaterial products. This clinic is still in development.

  
  

Competitive Advantages of BSD City and Simplr Health Regenerative Medicine and Longevity Clinic

BSD City’s SEZ offers a unique ecosystem supporting global collaboration, innovation, and clinical excellence, including:

• Streamlined regulatory processes for faster adoption of innovative treatments.

• Access to global expertise through partnerships with leaders in regenerative medicine.

• Collaboration with leading diagnostics, cGMP cell culturing, and research facilities within the BSD City BioMedical Centre.
  

These advantages combined with the location in the most dense populated part of Indonesia and together with a growing number of patients and purchasing power of patients, make the market conditions very favorable.

Next to the advantages of operating within a SEZ and the location of BSD City, the experience and proposition of Simplr itself will be very attractive.

1. International Standard Expertise and Globally Recognized Specialists

   Simplr Health’s medical team comprises internationally recognized specialists with extensive expertise in regenerative medicine, longevity treatments, and immune cell therapies for cancer. Our clinicians bring years of experience, global credentials, and advanced training from top-tier institutions. This foundation not only assures the highest quality of care but also keeps our clinic at the forefront of regenerative and cellular therapy advancements, allowing us to deliver cutting-edge, evidence-based therapies for both degenerative diseases and complex conditions such as cancer.
   

2. Regulatory-Approved Therapies from Leading Countries

   Simplr Health exclusively offers therapies approved by leading regulatory bodies in countries at the forefront of regenerative medicine, such as Japan, Australia, and the United States. This regulatory rigor ensures the safety, efficacy, and credibility of our offerings, distinguishing us from competitors that may operate in unregulated or gray areas. The therapies we provide have undergone extensive scrutiny and meet stringent international standards, allowing patients to have full confidence in their treatments, particularly for critical applications like immune cell therapy for cancer.  

3. Evidence-Based Promotion of Therapies

   Our clinic’s ability to promote treatments backed by functional and clinical data ensures that patients are informed by credible, data-driven results. Since our therapies have received regulatory approval, we can market them responsibly and transparently, building trust and establishing a high standard of accountability. This approach enables our patients to make well-informed decisions about their health and longevity, with clear evidence supporting each therapy’s potential, especially in advanced treatments for cancer and age-related degenerative diseases.  

4. Combinatorial Approaches and Proprietary Protocols for Optimized Outcomes

   Simplr Health takes a holistic and integrative approach to regenerative medicine, combining multiple treatment modalities to optimize patient outcomes. By leveraging proprietary protocols and cutting-edge technologies, guided by world-leading experts, we provide highly personalized combinatorial treatments that address the unique needs of each patient. Our ability to combine immune cell therapies for cancer with our degenerative disease treatments places Simplr Health at the top of the most comprehensive regenerative and cellular therapy clinics in the country, enhancing both patient outcomes and satisfaction.
   

5. Strategic Partnerships with Key Institutions

   Our relationships with renowned clinical and academic institutions, such as the Center for Digestive Diseases (CDD) and Kyoto University, along with credible professional organizations like the Australasian College of Sport and Exercise Physicians (ACSEP), A5M, and the Australasian College of Aesthetic Medicine (ACAM), provide Simplr Health with access to pioneering research, novel protocols, and continuous learning opportunities. These partnerships allow us to implement the latest breakthroughs in regenerative medicine, cellular therapy, and immunotherapy, directly benefiting patients through innovative and highly effective treatments.
   

6. Credibility of our Scientific Advisory Board (SAB)

   The Simplr Health Scientific Advisory Board, composed of esteemed professionals, actively contributes to our clinic with their extensive knowledge and insights. Their involvement assures adherence to the highest standards in clinical practice and lends credibility to our operations. Our SAB’s expertise in cellular and regenerative medicine fortifies our position as a leader in advanced therapies, reinforcing patient trust and ensuring that we remain at the cutting edge of medical research and regulatory compliance.

Comparison to Competitors

While Simplr Health prides itself on operating to the highest standards in regenerative medicine, many competitors may not uphold similar standards, creating clear points of differentiation:

• Competitors operating in Regulatory Gray Areas: Some competitors may offer treatments that fall into regulatory gray zones, lacking the formal approval and oversight that Simplr Health guarantees through its adherence to international standards.

• Limited Offerings Due to Clinical Trial Constraints of competitors: Competitors who operate solely within clinical trial frameworks are often limited in the treatments they can provide, restricting their ability to offer a comprehensive range of services and achieve optimized patient outcomes. Simplr Health’s regulatory-approved therapies allow us to deliver fully accessible treatments, including immune cell therapies for cancer and combinatorial protocols for degenerative diseases.

• Some competitors work with Sub-Standard or Under-Credentialed Clinical Staff: Simplr Health employs highly credentialed specialists recognized on a global scale, whereas competitors may rely on less qualified staff, potentially impacting treatment safety and effectiveness, especially in complex areas such as cancer immunotherapy.

• Therapeutic Products of competitors Lacking Safety and Efficacy Data: Unlike Simplr Health, which utilizes only regulatory-approved therapies backed by robust clinical data, some competitors may use products and protocols that lack sufficient validation, increasing risks for patients.

• Limited Service Offerings of competitors: Many competing clinics offer a narrow selection of treatments, which can limit the breadth and depth of patient care and diminish potential health outcomes. Simplr Health’s comprehensive combinatorial approach, particularly our capability to treat both degenerative diseases and cancer with immune cell therapies, ensures a wider range of options for more personalized and effective treatments.

• Competitors with Lack of Specialized Experience in Treating Specific Conditions: Simplr Health’s team has specialized knowledge and extensive experience in managing complex conditions like cancer and age-related diseases, allowing for targeted and effective treatment plans. Competitors may not have this level of expertise, potentially compromising patient care and outcomes.

• Inadequate Data Collection and Follow-Up Care: Simplr Health emphasizes continuous data collection and thorough follow-up care to monitor patient progress and adapt treatment plans as needed. Competitors may overlook this essential aspect, leading to lower treatment efficacy and patient satisfaction.
  

By maintaining the highest standards across all aspects of our operations, Simplr Health distinguishes itself as a trusted, data-driven, and patient-focused leader in regenerative medicine and longevity. Our commitment to safety, efficacy, and ethical practices—coupled with our unique capability in cancer immunotherapy and degenerative disease treatment—ensures that patients receive the most advanced, reliable, and beneficial treatments available today.

1. Jonsson et al. BMC Musculoskeletal Disorders (2016) 17:14

2. Muthiariny, Dewi Elvia, trans. "Jokowi Says Nearly 2 Million Indonesians Seek Healthcare Abroad." Edited by Petir Garda Bhwana. March 6, 2023.

4. Organization, staffing and management

4.3 Scientific Advisory Board

The clinic’s Scientific Advisory Board includes internationally recognized experts who bring deep expertise in regenerative and personalised medicine: